Nivolumab, a monoclonal antibody against programmed cell death-1 receptor, is increasingly used in advanced cancers. While nivolumab use enhances cancer therapy, it is associated with increased immune-related adverse events. We describe an elderly man who presented in ketoacidosis after receiving nivolumab for metastatic renal cell carcinoma. On presentation, he was hyperpneic and laboratory analyses showed hyperglycemia and anion-gapped metabolic acidosis consistent with diabetic ketoacidosis. No other precipitating factors, besides nivolumab, were identified. Pre-nivolumab blood glucose levels were normal. The patient responded to treatment with intravenous fluids, insulin and electrolyte replacement. He was diagnosed with insulin-dependent autoimmune diabetes mellitus secondary to nivolumab. Although nivolumab was stopped, he continued to require multiple insulin injection therapy till his last follow-up 7 months after presentation. Clinicians need to be alerted to the development of diabetes mellitus and diabetic ketoacidosis in patients receiving nivolumab.
Background
Understanding how cancer escapes host immune regulation has led to the development of cancer 'immunotherapy'. In particular, antibodies such as nivolumab, targeting and inhibiting programmed cell death 1 receptor (PD-1(PDCD1)), can result in the preferential activation of T-cells with specificity for cancer (1) . Multiple trials have already demonstrated significant response rates and improved survival with nivolumab in multiple neoplasms including melanoma (2, 3, 4, 5, 6, 7, 8, 9, 10, 11) , non-small-cell lung cancer (NSCLC) (2, 3, 4, 12, 13, 14, 15) and renal cell carcinoma (RCC) (2, 3, 4, 16, 17) .
However, inhibition of the PD-1 pathway results in a reduction of 'self-tolerance', with an apparent increase in immune-mediated adverse events (AE). Clinical trials investigating the efficacy of nivolumab in cancers have reported increased rates of autoimmune endocrinopathies, including: hypophysitis (5, 7, 8, 10, 11) , adrenal insufficiency (4, 5, 7, 10, 12) , thyroid disorders (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16, 18) Correspondence should be addressed to A S Lee Email lee.augustine@mayo.edu
Learning points:
• Diabetic ketoacidosis should be considered in the differential of patients presenting with metabolic acidosis following treatment with antibodies to programmed cell death-1 receptor (anti-PD-1).
• Autoimmune islet cell damage is the presumed mechanism for how insulin requiring diabetes mellitus can develop de novo following administration of anti-PD-1.
• Because anti-PD-1 works by the activation of T-cells and reduction of 'self-tolerance', other autoimmune disorders are likely to be increasingly recognized with increased use of these agents.
ID: 17-0174; March 2018 DOI: 10.1530/EDM- http://www.edmcasereports.com 2 and hyperglycemia (2, 3, 4, 6, 8, 15, 17) . We report a patient presenting critically ill with diabetic ketoacidosis (DKA) after receiving nivolumab. In addition, we provide a review of the literature reporting nivolumab-induced diabetes mellitus (DM). Acute care physicians' awareness of the acute complications of these novel therapies is essential for the timely management of these critically ill patients.
Case presentation
A Caucasian man, in his early seventies, reported to our emergency department with 3 days of dyspnea, abdominal pain, fatigue and polyuria. Symptoms were progressive despite drinking a significant amount of fluids to keep up with his subjective sense of dehydration. He denied fever, chest pain, edema and visual disturbances. One year earlier, he had undergone radical right nephrectomy and retroperitoneal lymph node dissection for stage IVB metastatic RCC (metastases to mesenteric lymph nodes and peritoneum). He had received 3 cycles of nivolumab, 3 mg/kg (300 mg, weight: 90 kg with BMI of 28.4) intravenously every 2 weeks, with his last infusion 10 days prior to his acute presentation. Notably, the patient was not enrolled in a clinical trial.
Other comorbidities were hypertension and chronic kidney disease that did not require renal replacement therapy. He was on lisinopril and aspirin. He had not been on any systemic glucocorticoids. There was no personal or family history of pancreatitis, DM or other autoimmune disorders.
Patient was afebrile and normotensive with a pulse of 88 beats per minute, respiratory rate of 28 breaths per minute and oxygen saturation of 97% while breathing ambient air. On examination, he was in moderate respiratory distress due to hyperpnea. There was absent breath sounds on the left lung base with dullness to percussion and decreased tactile vocal fremitus. The rest of his examination was unremarkable. Chest radiographs showed small bilateral pleural effusions (left greater than right) but otherwise clear lung fields.
Investigation
Laboratory analyses (Table 1) showed severe hyperglycemia (878 mg/dL) and an anion gap metabolic acidosis (anion gap: 21) associated with 'large' serum acetones and urine ketones. Arterial blood gas confirmed a primary metabolic acidosis (pH: 7.23, HCO 3 : 12) with partial respiratory compensation (PaCO 2 : 18). Multiple pre-admission outpatient fasting blood glucose levels, as recently as two weeks prior to admission, were normal (86-100 mg/ dL), although the HbA1c at admission was increased at 8.4%. Other metabolic derangements (hyponatremia and hyperkalemia) were related to ketoacidosis. Additional workup for possible acute pancreatitis, acute coronary syndrome or infectious process was unrevealing. A random C-peptide level was low (0.4 ng/mL) with concomitant blood glucose of 194 mg/dL. Serum for glutamic acid decarboxylase (GAD65) antibody was drawn at the time of the acute presentation, and when it proved negative on follow-up, testing for other less common autoantibodies (IA-2 and IAA) and human leukocyte antigen typing was considered but deferred by the patient and clinical team given unclear management implications (19) .
Treatment
The patient was diagnosed with DKA due to new-onset insulin-dependent autoimmune diabetes secondary to nivolumab. He was treated accordingly with intravenous hydration, insulin drip and electrolyte replacement. Thereafter, all the metabolic disturbances improved with resolution of hyperglycemia and acidemia. However, he continued to require insulin therapy and was subsequently discharged on subcutaneous insulin.
Outcome and follow-up
On follow-up, restaging computed tomography showed significant disease progression without pancreatic involvement. Nivolumab was stopped and changed to pazopanib (tyrosine kinase inhibitor). Despite remaining off PD-1 antagonists, the patient continued to require multiple daily insulin injections with insulin glargine (15 units twice daily) and aspartate (5 units with meals, weight 76 kg) at his last follow-up 7 months after hospital discharge. The patient subsequently died 8 months after his initial presentation due to complications of his metastatic RCC.
Discussion
Even though GAD65 antibodies were negative, the inappropriately low C-peptide and sudden onset and persistent hyperglycemia with presentation of DKA confirmed insulin-dependent DM. The repeatedly normal pre-nivolumab fasting blood glucose levels suggest the absence of diabetes prior to nivolumab, while the increased HbA1c at the time of admission suggests more proximal post-nivolumab development of hyperglycemia, diabetes and glycation of hemoglobin. In all, this affirms the causal relationship between nivolumab and the newonset DM presenting as DKA in our patient. We performed an extensive literature search of Medline database through February 2018 to identify all published case reports of anti-PD-1-induced DM. Search term used was nivolumab, pembrolizumab and ipilimumab. For each report, we extracted age, gender, cancer type, nature and time frame of presentation, HbA1c, presence of autoantibodies, prior or concurrent chemotherapeutics, systemic steroids use and whether anti-PD-1 therapy was resumed. Reports' references were screened and all pertinent case reports were added. Additionally, we had previously performed a comprehensive literature search to identify all published articles that have investigated the impact of nivolumab on patients with cancer. Search term used was nivolumab and limits applied were: human and English. We reviewed the title and abstract of each article for possible inclusion. Articles that explored the effect of nivolumab on patients with cancer were included. For each included study, the information extracted included cancer type, study period, study design, sample size, gender, nivolumab dose, AE including common terminology criteria for adverse events (CTCAE) grade 3 or 4, and specifically, rates of endocrinopathy. Published manuscripts and supplemental materials were reviewed thoroughly for rates of treatment-related AE. Data about AE of any grade and of grade 3 or higher were gathered. Rates of thyroid disease, hypothyroidism and/or hyperthyroidism, were registered. Rates of hyperglycemia and rates of DM diagnosis, if reported, were also assembled and presented in tabular format. Our literature search produced 155 potential literature citations. After reviewing studies' title and/or abstract, a total of 17 studies were included (details are outlined in Tables 2 and 3) .
Multiple trials have reported hyperglycemia as a potential AE with estimated risks of 0.5-11% (details are outlined in Tables 2 and 3 207 (70) 41 (14) 10 (3) 126 (61) 19 (9) 6 (3) 3 (1) 29 (85) 6 (18) 3 (9) NR Immunotherapy in general, and nivolumab in specific, has revolutionized cancer therapy, and their use is rapidly growing. Consequently, the number of patients exposed to nivolumab will increase and the total number of patients experiencing AE will expectedly increase (24) .
AEs during nivolumab treatment are frequent and range from 40% to 98%. Most commonly, they include fatigue, rash, itching, diarrhea and infusion site reactions. They are largely managed by symptomatic and supportive care (25) . The severe AEs (CTCAE grade 3 or 4) are estimated to occur between 5% and 72%.They include pneumonitis, hepatitis and cytopenias. They are typically managed by discontinuing nivolumab and administering systemic corticosteroids (2, 25) . Limited data noted suggest treating nivolumab-induced autoimmune DM are unlikely to be effective once DM has developed, and better understanding of why some individuals develop this complication is required before potential therapeutic and even preventative interventions might be identified.
The PD-1 pathway plays a central role in the regulation of autoimmune diabetes (26) . Blockade of PD-1 can precipitate type 1 diabetes in mice models across all ages (27) and mechanisms may involve both humoral and cellular autoimmunity (19) . However, there remain significant gaps in understanding the interaction between PD-1 pathway and autoimmune diabetes. Sparse data are available regarding the time course, dose relationship, effect of concurrent immunotherapeutic or chemotherapeutic agents and management (e.g. immunomodulatory agents). Despite being an uncommon AE, developing irreversible insulin-dependent DM is life 86 (91) 51 (54) 22 (23) NR ( 311 (99) 136 (45) 40 (13) NR ( (69) 30 (10) 23 (8) 13 ¶ *Number of total patients assessed for adverse events may be different from patients included in the study; patients may had more than one adverse events; related adverse events if it was reported; † any grade; related adverse events if it was reported; ‡ with diabetes; § does not specify if diabetes or not; ¶ no cases of diabetes.
CTCAE, common terminology criteria for adverse events; NR, not reported. ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; COPP, cyclophosphamide/vincristin/prednisone/procarbazine; DKA, diabetic ketoacidosis; GAD65, glutamic acid decarboxylase 65; IAA, insulin autoantibodies; IA-2, tyrosine phosphatase-related islet antigen 2; ICE, ifosfamide/carboplatin/etoposide; NR, not reported; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; SCC, squamous cell carcinoma; SCLC, small cell lung cancer; ZnT8A, zinc transporter 8 autoantibody.
